menu
    • menu
    [{"orgOrder":0,"company":"Biofabri","sponsor":"Fundaci\u00f3n Investigaci\u00f3n en Urolog\u00eda","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin Vaccine","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofabri \/ Fundaci\u00f3n Investigaci\u00f3n en Urolog\u00eda","highestDevelopmentStatusID":"8","companyTruncated":"Biofabri \/ Fundaci\u00f3n Investigaci\u00f3n en Urolog\u00eda"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ Biofabri","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Biofabri"},{"orgOrder":0,"company":"Biofabri","sponsor":"TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Live-Attenuated Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium"},{"orgOrder":0,"company":"Biofabri","sponsor":"South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Live-Attenuated Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative"},{"orgOrder":0,"company":"Biofabri","sponsor":"South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Live-Attenuated Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"BCG Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Bharat Biotech"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"Biofabri","sponsor":"Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Live-Attenuated Mycobacterium Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofabri \/ Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative"}]

    Find Clinical Drug Pipeline Developments & Deals by Biofabri

    Menu

    Biofabri

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : IAVI

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IAVI, Biofabri Start IMAGINE Trial for Tuberculosis Vaccine Candidate MTBVAC

                            Details : MTBVAC is a live-attenuated vaccine candidate, derived from a human isolate of Mycobacterium tuberculosis. It is being evaluated to prevent active TB lung disease in adolescents and adults.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 26, 2025

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : IAVI

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bharat Biotech Begins Clinical Trials of TB Vaccine on Adults in India

                            Details : Mtbvac, the spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis, which is under clinical development for the treatment of tuberculosis in adults.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 24, 2024

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : IAVI

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC

                            Details : Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : IAVI

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bharat Biotech and Biofabri Partner to Develop, Manufacture and Distribute a Novel TB Vaccine, MTBVAC

                            Details : This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, w...

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 16, 2022

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

                            Details : MTBVAC (Live-Attenuated Tuberculosis Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tuberculosis.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 23, 2021

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Calmette-Guérin Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Fundación Investigación en Urología

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

                            Details : Bacillus Calmette-Guérin Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 12, 2019

                            Lead Product(s) : Bacillus Calmette-Guérin Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Fundación Investigación en Urología

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates

                            Details : MTBVAC (Live-Attenuated Tuberculosis Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 24, 2018

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adul...

                            Details : MTBVAC (Live-Attenuated Tuberculosis Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Tuberculosis.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 06, 2016

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Biofabri

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Mycobacterium Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vacci...

                            Details : MTBVAC (Live-Attenuated Mycobacterium Tuberculosis Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.

                            Product Name : MTBVAC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 17, 2013

                            Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Mycobacterium Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth